Carmell Therapeutics Corp... (CTCX)
0.44
-11.11%
At close: Jan 10, 2025, 3:59 PM
Company Description
Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging.
Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing.
The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.
Carmell Therapeutics Corporation
| Country | United States |
| IPO Date | Sep 23, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Kendra Bracken-Ferguson |
Contact Details
Address: 2403 Sidney Street Pittsburgh, Pennsylvania United States | |
| Website | https://www.carmellrx.com |
Stock Details
| Ticker Symbol | CTCX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001842939 |
| CUSIP Number | 142922103 |
| ISIN Number | US1429221039 |
| Employer ID | 00-0000000 |
| SIC Code | 6770 |
Key Executives
| Name | Position |
|---|---|
| Kendra Bracken-Ferguson | Chief Executive Officer |
| Bryan J. Cassaday | Chief Financial Officer |
| Dr. James Burgess M.D. | Founder |
| Dr. Lee Weiss Ph.D. | Founder |
| Dr. Phil Campbell Ph.D. | Founder and Chief Scientific Officer |
| Rajiv Sarman Shukla | Executive Chairman |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 08, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Jan 03, 2025 | 424B3 | Filing |
| Jan 03, 2025 | 8-K | Current Report |
| Dec 31, 2024 | 424B3 | Filing |
| Dec 31, 2024 | 8-K | Current Report |
| Dec 06, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 20, 2024 | 8-K | Current Report |
| Nov 19, 2024 | S-8 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | 424B3 | Filing |